The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
BONE MINERAL DENSITY IN MEN TREATED WITH SYNTHETIC GONADOTROPIN-RELEASING HORMONE AGONISTS FOR PROSTATIC CARCINOMA
Abstract
PURPOSE: We evaluate the relationship between the use of synthetic gonadotropin-releasing hormone (Gn-RH) agonists and bone loss in men. MATERIALS AND METHODS: Bone mineral density and parameters of mineral metabolism were evaluated in 12 patients with stage C prostatic carcinoma before and after 6, 12 and 18 months of treatment with 3.75 mg. triptorelin intramuscularly every 4 weeks. RESULTS: Of the 12 patients 9 were evaluated after 6, 7 after 12 and 6 after 18 months of therapy. In comparison with month 0, the lumbar and femoral neck bone mineral density tended to decrease at month 6 (-3 and -2.7%, p = 0.31 and 0.17, respectively), at month 12 (-4.6 and -3.9%, p = 0.13 and 0.13) and at month 18 (-7.1 and -6.6%, p = 0.12 and 0.027). A second analysis revealed that the lumbar and femoral neck bone mineral density was significantly decreased on the last evaluation compared to month 0 (p = 0.05 and 0.028, respectively). The serum osteocalcin was increased during treatment, suggesting an accelerated bone turnover in men treated with Gn-RH agonists. CONCLUSIONS: The use of Gn-RH agonists in men may induce an accelerated bone loss. Further studies are needed to confirm these results and to evaluate the incidence of osteoporotic fractures in men treated with Gn-RH agonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dawson-Hughes, B., Harris, S. S., Krall, E. A., & Dallal, G. E. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709043371003 · Cited by 2,277
Guidelines for diagnosis and management of osteoporosis
Kanis, J. A., Delmas, P., Burckhardt, P., Cooper, C., & Torgerson, D. (1997) · Osteoporosis International · doi:10.1007/bf01623782 · Cited by 790
ŠTĚPÁN, J. J., LACHMAN, M., ZVĚŘINA, J., PACOVSKÝ, V., & BAYLINK, D. J. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-69-3-523 · Cited by 424
Increases in Bone Density During Treatment of Men with Idiopathic Hypogonadotropic Hypogonadism*
FINKELSTEIN, J. S., KLIBANSKI, A., NEER, R. M., DOPPELT, S. H., ROSENTHAL, D. I., SEGRE, G. V., & CROWLEY, W. F. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-69-4-776 · Cited by 356
Townsend, M. F., Sanders, W. H., Northway, R. O., & Graham, S. D. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970201)79:3<545::aid-cncr17>3.0.co;2-3 · Cited by 260
Osteoporosis in Men with Hyperprolactinemic Hypogonadism
GREENSPAN, S. L., NEER, R. M., RIDGWAY, E. C., & KLIBANSKI, A. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-104-6-777 · Cited by 250
Management of male osteoporosis: report of the UK Consensus Group
Eastell, R. (1998) · QJM · doi:10.1093/qjmed/91.2.71 · Cited by 191
Sex hormones and bone mineral density in elderly men
Murphy, S., Khaw, K.-T., Cassidy, A., & Compston, J. E. (1993) · Bone and Mineral · doi:10.1016/s0169-6009(08)80022-0 · Cited by 187
Goldray, D. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.2.288 · Cited by 174
Osteopenia and Bone Fractures in a Man With Anorexia Nervosa and Hypogonadism
Rigotti, N. A., Neer, R. M., & Jameson, L. (1986) · JAMA · doi:10.1001/jama.1986.03380030087034 · Cited by 77
Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma
Waibel-Treber, S., Minne, H. W., SCHARLA, S. H., Bremen, T., Ziegler, R., & LEYENDECKER, G. (1989) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a136912 · Cited by 67
Osteoporosis occurring in two patients receiving LHRH analogs for carcinoma of the prostate
Collinson, M. P., TYRRELL, C. J., & Hutton, C. (1994) · Calcified Tissue International · doi:10.1007/bf00295959 · Cited by 31
Overview of role of BMD measurements in managing osteoporosis
Ryan, P. J. (1997) · Seminars in Nuclear Medicine · doi:10.1016/s0001-2998(97)80024-4 · Cited by 22
Ylikorkala, O., Nilsson, C.-G., Hirvonen, E., & Viinikka, L. U. (1990) · Gynecological Endocrinology · doi:10.3109/09513599009024979 · Cited by 21
Relationship between gonadotrophin-releasing hormone analogue therapy and bone loss; a review
Fraser, I. S. (1991) · Reproduction Fertility and Development · doi:10.1071/rd9910061 · Cited by 7
Cited by
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Mohler, J., Bahnson, R. R., Boston, B., Busby, J. E., D'Amico, A., Eastham, J. A., Enke, C. A., George, D., Horwitz, E. M., Huben, R. P., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0012 · Cited by 897
Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
Nguyen, P. L., Alibhai, S. M. H., Basaria, S., D’Amico, A. V., Kantoff, P. W., Keating, N. L., Penson, D. F., Rosario, D. J., Tombal, B., & Smith, M. R. (2015) · European Urology · doi:10.1016/j.eururo.2014.07.010 · Cited by 831
Vanderschueren, D., Vandenput, L., Boonen, S., Lindberg, M. K., Bouillon, R., & Ohlsson, C. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0003 · Cited by 717
Changes in body composition during androgen deprivation therapy for prostate cancer
Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8299 · Cited by 697
Metadata
- Authors
- MAILLEFERT, J. F., SIBILIA, J., MICHEL, F., SAUSSINE, C., JAVIER, R. M., & TAVERNIER, C.
- Venue
- Journal of Urology
- Published
- 1999-04
- Volume
- 161
- Issue
- 4
- Pages
- 1219-1222
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2005383842
- Cited by
- 308
- References
- 15
- FWCI
- 13.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.